Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: Amino acid substitutions in HCV core region as predictor of mortality after first treatment

Intervirology

Volumn 52, Issue 4, 2009, Pages 179-188

  Ogura, Suguru ^a   Akuta, Norio ^a   Hirakawa, Miharu ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Core region; Hepatitis C virus; Hepatocellular carcinoma; Mortality

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS;

EID: 67449143101     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000225193     Document Type: Article

References (38)

1. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo QL, Kuo G: Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12: 589-591.
2. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D: Progress of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695. (Pubitemid 28549142)
3. Dusheiko GM: The natural course of chronic hepatitis C: implicates for clinical practice. J Viral Hepatol 1998; 5(suppl 1):9-12. (Pubitemid 128706701)
4. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepa titis: a prospective observation of 2,215 pa tients. J Hepatol 1998; 28: 930-938. (Pubitemid 28275969)
5. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.
6. Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H: Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) * 0201 allele. J Med Virol 2001; 64: 109-116.
7. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Group. N Engl J Med 1989; 321: 1501-1506.
8. Di Bisceglie AM, Martin P, Kassianides C, Lister-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofinagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
9. Liver Cancer Study Group of Japan: Survey and follow-up study of primary liver cancer in Japan: Report 14. Acta Hepatol Jpn 2000; 40: 799-811.
10. Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, Koga M, Nakata K, Eguchi K, Yano M: Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer (Phila) 2002; 95: 331-339. (Pubitemid 34787600)
11. Ohishi W, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, Kamiyasu M, Nakanishi T, Tazuma S, Chayama K: Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003; 38: 894-900. (Pubitemid 37011585)
12. Saneto H, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H: Clinicopathological features, background liver disease, and survival analysis of HCVpositive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol 2008; 43: 975-981.
13. Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, Takaki S, Soo CJ, Imamura M, Kawakami Y, Takahashi S, Itamoto T, Asahara T, Arihiro K, Chayama K: Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 2008; 43: 550-557.
14. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Association of amino acid substitution pattern in core protein if hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380. (Pubitemid 41003622)
15. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90. (Pubitemid 41783847)
16. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictive factors of early and sustained responses to peginterferon + ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and lowdensity lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410. (Pubitemid 46185701)
17. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictors of viral kinetics to peginterferon + ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686-1695. (Pubitemid 47479887)
18. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50: 361-368. (Pubitemid 350014920)
19. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H: A matched case-controlled study of 48 and 72 weeks of peginterferon + ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-458.
20. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE: Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007; 81: 8211-8224. (Pubitemid 47101507)
21. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Amino acid substitution in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007; 46: 1357-1364. (Pubitemid 350155517)
22. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Substitutions of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated α -fetoprotein in patients without hepatocellular carcinoma. J Med Virol 2008; 80: 1354-1362. (Pubitemid 351897406)
23. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, Arase Y, Murashima N, Kumada H: Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Hepatol Res 2000; 18: 252-266.
24. Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, Zadak M, Babiel R: Fully automated quantification of hepatitis C virus RNA in human plasma and human serum by the Cobas® AmpliPrep/Cobas® TaqMan® System. J Clin Virol 2007; 38: 326-333.
25. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-9528. (Pubitemid 120016475)
26. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C: Comparison of fulllength sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
27. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81. (Pubitemid 26017933)
28. Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, Yoon S, Saito T, Kawata S, Hotta H: Identification of hepatitis C virus subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 2003; 41: 2835-2841. (Pubitemid 36842267)
29. Giménez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, Sánchez-Fueyo A, Barrera JM, Llovet JM, Bruix J, Sánchez-Tapias JM, Rodés J, Saiz JC: High amino acid variability within the NS5A of hepatitis C virus is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology 2001; 34: 158-167. (Pubitemid 32591496)
30. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Efficacy of low-dose intermittent interferon- α monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon + ribavirin combination therapy. J Med Virol 2008; 80: 1363-1369. (Pubitemid 351897407)
31. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801. (Pubitemid 23174709)
32. Ikeda K, Saitoh S, Koide I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis. Hepatology 1993; 18: 47-53.
33. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Kobayashi M, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130. (Pubitemid 29168746)
34. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, Osuga T: Multivariate analysis of risk factors hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31: 552-558. (Pubitemid 26288425)
35. Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(suppl 1):34-38.
36. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S: Hepatitis C virus-related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136. (Pubitemid 30430422)
37. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer (Phila) 2000; 89: 53-59.
38. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M: Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114. (Pubitemid 40096811)